Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK

Bevacizumab is an anti-vascular endothelial growth factor monoclonal antibody that may prolong survival in ovarian and cervical cancer when given in combination with chemotherapy. It works by blocking the signalling pathways that are required for tumour angiogenesis, potentially limiting the cancer’...

Descripción completa

Detalles Bibliográficos
Autores principales: Plummer, Chris, Michael, Agnieszka, Shaikh, Ghazia, Stewart, Michael, Buckley, Lynn, Miles, Tracie, Ograbek, Agnes, McCormack, Terry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738076/
https://www.ncbi.nlm.nih.gov/pubmed/31182765
http://dx.doi.org/10.1038/s41416-019-0481-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738076/
https://www.ncbi.nlm.nih.gov/pubmed/31182765
http://dx.doi.org/10.1038/s41416-019-0481-y

Ejemplares similares